ENDOCYTE ANNOUNCES PHASE 2B TARGET TRIAL RESULTS EVALUATING VINTAFOLIDE/DOCETAXEL COMBINATION IN NON-SMALL CELL LUNG CANCER (NSCLC) MET THE PRIMARY ENDPOINT OF IMPROVED PROGRESSION FREE SURVIVAL
Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer